

Chengjie Xiong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7202284/publications.pdf>

Version: 2024-02-01

115
papers

4,941
citations

134610

34
h-index

120465

65
g-index

137
all docs

137
docs citations

137
times ranked

6516
citing authors

#	ARTICLE	IF	CITATIONS
1	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.4	4
2	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limits—Application to diagnosing early stage Alzheimer disease. <i>Statistical Methods in Medical Research</i> , 2022, 31, 882-898.	0.7	1
3	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 2570-2581.	0.4	8
4	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	4.9	72
5	Effect of Race on Prediction of Brain Amyloidosis by Plasma A β ⁴² /A β ⁴⁰ , Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, .	1.5	63
6	Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
7	Item response theory analysis of the Clinical Dementia Rating. <i>Alzheimer's and Dementia</i> , 2021, 17, 534-542.	0.4	14
8	Lack of association between acute stroke, post-stroke dementia, race, and β ² -amyloid status. <i>NeuroImage: Clinical</i> , 2021, 29, 102553.	1.4	12
9	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. <i>Neurology: Genetics</i> , 2021, 7, e571.	0.9	27
10	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
11	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	4.9	26
12	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. <i>BMJ Open</i> , 2021, 11, e050820.	0.8	8
13	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 153.	3.0	3
14	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , 2021, 97, e1823-e1834.	1.5	35
15	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.5	16
16	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	11.7	17
17	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. <i>Neurobiology of Aging</i> , 2020, 96, 165-175.	1.5	13
18	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	1.4	17

#	ARTICLE	IF	CITATIONS
19	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	15.2	351
20	Identifying blood pressure loci whose effects are modulated by multiple lifestyle exposures. <i>Genetic Epidemiology</i> , 2020, 44, 629-641.	0.6	6
21	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.4	13
22	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 589-597.	0.4	25
23	High-precision plasma β -amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , 2019, 93, e1647-e1659.	1.5	514
24	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 1149-1159.	0.4	45
25	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 1448-1457.	0.4	7
26	Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 450-457.	1.8	2
27	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	3.7	36
28	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.4	72
29	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
30	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. <i>Alzheimer's and Dementia</i> , 2019, 15, 506-514.	0.4	28
31	ICP46: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2019, 15, P48.	0.4	0
32	Incorporating Biomarkers to Improve Statistical Power of Immunotherapeutic Neoadjuvant Clinical Trials in Patients with Triple-Negative Breast Cancer. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 210-219.	0.6	0
33	Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	208
34	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 264.	4.5	227
35	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neurobiology of Aging</i> , 2019, 75, 42-50.	1.5	36
36	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , 2018, 14, 1460-1469.	0.4	192

#	ARTICLE	IF	CITATIONS
37	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
38	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 745-756.	1.2	45
39	Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 869-879.	0.4	113
40	Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.	0.4	50
41	P1-023: MASS SPECTROMETRY-BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P273.	0.4	2
42	O3-14-01: NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIP-1, NEUROGRANIN, SNAP-25 AND YKL-40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). <i>Alzheimer's and Dementia</i> , 2018, 14, P1059.	0.4	0
43	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 669-677.	1.2	14
44	MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE. <i>Journal of Prevention of Alzheimer's Disease</i> , 2018, 5, 1-10.	1.5	2
45	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 669-676.	1.8	9
46	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 741-753.	2.8	17
47	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.4	51
48	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <i>Brain</i> , 2018, 141, 3233-3248.	3.7	24
49	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018, 91, e1295-e1306.	1.5	193
50	A novel cognitive disease progression model for clinical trials in autosomal dominant Alzheimer's disease. <i>Statistics in Medicine</i> , 2018, 37, 3047-3055.	0.8	31
51	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , 2018, 19, 406-416.	1.4	76
52	Preclinical Alzheimer's disease and longitudinal driving decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 74-82.	1.8	44
53	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2017, 56, 25-32.	1.5	57
54	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	1.6	42

#	ARTICLE	IF	CITATIONS
55	Risk of incident clinical diagnosis of Alzheimer's disease—type dementia—attributable to pathology—confirmed vascular disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 613-623.	0.4	30
56	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P47.	0.4	0
57	[P3â€“263]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER'S DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1043.	0.4	0
58	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P768.	0.4	0
59	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. <i>Alzheimer's and Dementia</i> , 2017, 13, P44.	0.4	0
60	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P125.	0.4	0
61	[P2â€“209]: QUANTIFYING PRECLINICAL STAGES OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) AND THE ASSOCIATED OVERALL BIOMARKER SIGNATURE ACROSS MODALITIES USING THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). <i>Alzheimer's and Dementia</i> , 2017, 13, P689.	0.4	0
62	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. <i>Alzheimer's and Dementia</i> , 2017, 13, P186.	0.4	0
63	[O2â€“01â€“05]: IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE. <i>Alzheimer's and Dementia</i> , 2017, 13, P550.	0.4	0
64	[O2â€“05â€“03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND <i>IN VIVO</i> AMYLOID IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P561.	0.4	0
65	[O3â€“10â€“01]: CROSS-SECTIONAL AND LONGITUDINAL COMPARISONS OF COGNITION AND BIOMARKERS AMONG COGNITIVELY NORMAL INDIVIDUALS AGED 42 TO 65 YEARS WITH A FAMILY HISTORY OF EITHER AUTOSOMAL DOMINANT AD (ADAD) OR LATE-ONSET AD (LOAD). <i>Alzheimer's and Dementia</i> , 2017, 13, P923.	0.4	0
66	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P186.	0.4	0
67	Estimating correlation between multivariate longitudinal data in the presence of heterogeneity. <i>BMC Medical Research Methodology</i> , 2017, 17, 124.	1.4	6
68	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45
69	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P87.	0.4	0
70	P4â€“004: Planning Dose Escalation in Phase III Clinical Trials May Prevent Underpowered Trials and Mitigate the Increase in Sample Size or Duration of Adaptive Trials. <i>Alzheimer's and Dementia</i> , 2016, 12, P1015.	0.4	0
71	P4â€“150: Preclinical Alzheimer's Disease Predicts Longitudinal Onset of Driving Difficulties Among Cognitively Normal Persons. <i>Alzheimer's and Dementia</i> , 2016, 12, P1071.	0.4	0
72	O2â€“08â€“05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P246.	0.4	0

#	ARTICLE	IF	CITATIONS
73	O3-09-05: The Dian-Nacc UDS Comparison Study: Rates of Cognitive Decline. , 2016, 12, P309-P309.		0
74	F4â€³â€²: The Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's and Dementia, 2016, 12, P326.	0.4	0
75	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
76	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiology of Aging, 2016, 43, 23-33.	1.5	49
77	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	2.8	82
78	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	4.9	87
79	A multiple imputation approach to the analysis of clustered interval-censored failure time data with the additive hazards model. Computational Statistics and Data Analysis, 2016, 103, 242-249.	0.7	7
80	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology, 2016, 86, 1499-1506.	1.5	39
81	P1-104: CSF tau predicts working memory and global cognitive decline in autosomal dominant Alzheimer's disease. , 2015, 11, P379-P379.		0
82	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease. , 2015, 11, P255-P255.		0
83	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease. , 2015, 11, P533-P534.		1
84	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
85	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P538-P538.		0
86	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PIB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0
87	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	1.2	47
88	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P8-P9.		0
89	Bivariate correlation coefficients in familyâ€™type clustered studies. Biometrical Journal, 2015, 57, 1084-1109.	0.6	12
90	Predicting Clinical Binary Outcome Using Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open - Angle Glaucoma. Journal of Biometrics & Biostatistics, 2015, 06, .	4.0	1

#	ARTICLE	IF	CITATIONS
91	Factors Associated With the Onset and Persistence of Post-“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	4.5	59
92	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P674-P674.		0
93	P1-106: Longitudinal biomarker connectivity on middle-aged asymptomatic individuals and optimal design on prevention trials of Alzheimer's disease. , 2015, 11, P379-P379.		0
94	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
95	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 2015, 72, 1029.	4.5	237
96	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	3.0	101
97	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27
98	Interrater Reliability of the Record of Driving Errors (RODE). American Journal of Occupational Therapy, 2015, 69, 6902350020p1-6902350020p6.	0.1	10
99	IC-P-008: REGIONAL PIB DEPOSITION AND CSF A β 42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P11-P11.		0
100	P1-143: LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT. , 2014, 10, P352-P353.		0
101	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.5	391
102	Optimizing parameters in clinical trials with a randomized start or withdrawal design. Computational Statistics and Data Analysis, 2014, 69, 101-113.	0.7	4
103	S3-01-01: SCREENING FOR ALZHEIMER'S DISEASE IN COGNITIVELY NORMAL OLDER ADULTS: SUBJECTIVE COGNITIVE DECLINE VERSUS INFORMANT REPORT. , 2014, 10, P200-P200.		0
104	O2-05-04: REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P173-P173.		0
105	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
106	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
107	IC-O2-01: How do we define amyloid positivity in an asymptomatic population? Comparison of CSF, quantitative PET and clinical PET examinations. , 2013, 9, P6-P6.		0
108	Youden Index and Associated Cut-Points for Three Ordinal Diagnostic Groups. Communications in Statistics Part B: Simulation and Computation, 2013, 42, 1213-1234.	0.6	56

#	ARTICLE	IF	CITATIONS
109	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2012, 8, P244.	0.4	1
110	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
111	Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study. <i>Archives of Neurology</i> , 2011, 68, 1313.	4.9	55
112	A Parametric Comparison of Diagnostic Accuracy with Three Ordinal Diagnostic Groups. <i>Biometrical Journal</i> , 2007, 49, 682-693.	0.6	22
113	Measuring and estimating diagnostic accuracy when there are three ordinal diagnostic groups. <i>Statistics in Medicine</i> , 2006, 25, 1251-1273.	0.8	84
114	Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. <i>Journal of Applied Statistics</i> , 0, , 1-25.	0.6	2
115	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	2